Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) EPS (Weighted Average and Diluted) (2018 - 2025)

Ironwood Pharmaceuticals (IRWD) has disclosed EPS (Weighted Average and Diluted) for 12 consecutive years, with -$0.01 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) fell 200.0% to -$0.01 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $0.13 through Dec 2025, up 1400.0% year-over-year, with the annual reading at $0.15 for FY2025, 1400.0% up from the prior year.
  • EPS (Weighted Average and Diluted) hit -$0.01 in Q4 2025 for Ironwood Pharmaceuticals, down from $0.23 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $2.39 in Q2 2021 to a low of -$6.84 in Q2 2023.
  • Historically, EPS (Weighted Average and Diluted) has averaged -$0.11 across 5 years, with a median of $0.18 in 2025.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): plummeted 3357.14% in 2023 and later soared 1500.0% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at $0.25 in 2021, then grew by 8.0% to $0.27 in 2022, then tumbled by 103.7% to -$0.01 in 2023, then surged by 200.0% to $0.01 in 2024, then crashed by 200.0% to -$0.01 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for IRWD at -$0.01 in Q4 2025, $0.23 in Q3 2025, and $0.14 in Q2 2025.